 |
| Intelligent anti-aging skin care based on independent research |
| Lose wrinkles, keep your bank account! |
|
|
|
|
 |
You are here: Skin Care Research >
Author: Broder KW, Cohen SR
Author affiliation: Fresh Start Craniofacial Fellow, Clinical Instructor, University of California, Division of Plastic and Reconstructive Surgery, San Diego, CA, USA. kbroder@ucsd.edu
Publication date & source: 2006.05, Expert Rev Med Devices., 3(3):281-9.
The ideal soft-tissue filler for wrinkles and skin defects should be safe, biocompatible, resistant to phagocytosis, persist and maintain its volume without being resorbed or degraded. ArteFill, an improved, next-generation derivative of Artecoll, is expected to become the first and only FDA-approved permanent filler for use in the USA in 2006 and will be available worldwide. ArteFill consists of polymethylmethacrylate microspheres suspended in a 3.5% solution of bovine collagen containing 0.3% lidocaine. In this article, the pathophysiology, efficacy and safety of ArteFill are discussed and details of its injection technique are provided. Insight into the pharmacoeconomic value of ArteFill over nonpermanent fillers and ArteFill's unique role in the growing world market of dermal fillers is provided.
Home | About Us | Contact Us | Ask a Question | Resources Copyright © 1999-2008 by Dr. G. Todorov / SmartSkinCare.com Site Disclaimer | Copyright Certification
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
